•Leadership watch: LENZ, CooperCompanies CEOs step down, among exec changes•Roivant, Priovant report positive phase 3 NIU data for brepocitinib•Industry payments tied to higher prescribing volume, costs•FDA approves Xbrane Biopharma's Lucentis biosimilar•AAO Foundation and VSP award over $200K in OD scholarships•Leadership watch: LENZ, CooperCompanies CEOs step down, among exec changes•Roivant, Priovant report positive phase 3 NIU data for brepocitinib•Industry payments tied to higher prescribing volume, costs•FDA approves Xbrane Biopharma's Lucentis biosimilar•AAO Foundation and VSP award over $200K in OD scholarships
HEADLINES
FEATURED
Oral small molecule is designed to correct protein misfolding for RHO gene mutations, the root cause of RHO-adRP; phase 1/2 clinical study currently underway.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
